KRAS and cancer: Targeting Ras membrane association through PI4KA inhibitors represents a new indirect targeting strategy and holds promise for KRAS mutant cancer patients.515,516 Enhanced dependence on lipid biosynthesis and β-oxidation of KRAS mutant cancer cells also leads to new approaches to target the metabolic vulnerability of KRAS-driven cancers.466–468